<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Septerna, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/septerna-inc-common-stock</link>
    <description>Latest news and press releases for Septerna, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 13 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/septerna-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bec678dffbe2df117cb5.webp</url>
      <title>Septerna, Inc. Common Stock</title>
      <link>https://6ix.com/company/septerna-inc-common-stock</link>
    </image>
    <item>
      <title>Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or</description>
    </item>
    <item>
      <title>Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-pipeline-progress-and-reports-fourth-quarter-and-full-year-2025-financial-results-13</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-pipeline-progress-and-reports-fourth-quarter-and-full-year-2025-financial-results-13</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in</description>
    </item>
    <item>
      <title>Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-positive-phase-1-data-for-sep-631-an-oral-mrgprx2-nam-for-the-treatment-of-mast-cell-driven-diseases-and-outlines-initial-phase-2-development-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-positive-phase-1-data-for-sep-631-an-oral-mrgprx2-nam-for-the-treatment-of-mast-cell-driven-diseases-and-outlines-initial-phase-2-development-strategy</guid>
      <pubDate>Sun, 01 Mar 2026 05:00:00 GMT</pubDate>
      <description>SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg</description>
    </item>
    <item>
      <title>Septerna to Present at TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-to-present-at-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-to-present-at-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of</description>
    </item>
    <item>
      <title>Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-reports-inducement-grant-under-210500097</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-reports-inducement-grant-under-210500097</guid>
      <pubDate>Tue, 10 Feb 2026 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company’s Board of Directors granted an inducement award to Mark A. Wilson, Septerna’s Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company’s 2026 Inducement Plan. The award w</description>
    </item>
    <item>
      <title>Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-data-phase-1-130000921</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-data-phase-1-130000921</guid>
      <pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma &amp; Immunology (AAAAI) Annual Meeting, taking place February 27-March 2, 2026, in Philadelphia. SEP-631 is a selective oral small molecule Mas-related G p</description>
    </item>
    <item>
      <title>Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-expands-leadership-appointment-industry-210500562</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-expands-leadership-appointment-industry-210500562</guid>
      <pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. “We are</description>
    </item>
    <item>
      <title>Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
      <pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G</description>
    </item>
    <item>
      <title>Septerna to Participate in 8th Annual Evercore Healthcare Conference</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-participate-8th-annual-evercore-healthcare-conference-2025-11-25</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-participate-8th-annual-evercore-healthcare-conference-2025-11-25</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of</description>
    </item>
    <item>
      <title>Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-company-progress-and-reports-third-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-company-progress-and-reports-third-quarter-2025-financial-results</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust</description>
    </item>
    <item>
      <title>Septerna to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-participate-upcoming-investor-conferences-2025-11-03</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-participate-upcoming-investor-conferences-2025-11-03</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G</description>
    </item>
    <item>
      <title>Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-appoints-veteran-biotechnology-leader-keith-gottesdiener-md-its-board</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-appoints-veteran-biotechnology-leader-keith-gottesdiener-md-its-board</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of</description>
    </item>
    <item>
      <title>Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-dosing-first-participants-phase-1-clinical-trial-sep-631-oral</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-dosing-first-participants-phase-1-clinical-trial-sep-631-oral</guid>
      <pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
      <description>Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug.</description>
    </item>
    <item>
      <title>Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-business-progress-and-reports-second-quarter-2025-financial</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-business-progress-and-reports-second-quarter-2025-financial</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program,</description>
    </item>
    <item>
      <title>Septerna to Present at Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-jefferies-global-healthcare-conference-2025-05-29</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-jefferies-global-healthcare-conference-2025-05-29</guid>
      <pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled</description>
    </item>
    <item>
      <title>Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-business-progress-and-reports-first-quarter-2025-financial</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-highlights-business-progress-and-reports-first-quarter-2025-financial</guid>
      <pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
      <description>Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments</description>
    </item>
    <item>
      <title>Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-provides-corporate-overview-and-reports-fourth-quarter-and-full-year-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-provides-corporate-overview-and-reports-fourth-quarter-and-full-year-2024</guid>
      <pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
      <description>Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1</description>
    </item>
    <item>
      <title>Septerna to Present at TD Cowen 45th Annual Health Care Conference</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-td-cowen-45th-annual-health-care-conference-2025-02-26</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-present-td-cowen-45th-annual-health-care-conference-2025-02-26</guid>
      <pubDate>Wed, 26 Feb 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G</description>
    </item>
    <item>
      <title>Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-discontinuation-sep-786-phase-1-clinical-trial-and-plans-advance</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-announces-discontinuation-sep-786-phase-1-clinical-trial-and-plans-advance</guid>
      <pubDate>Tue, 18 Feb 2025 05:00:00 GMT</pubDate>
      <description>Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct</description>
    </item>
    <item>
      <title>Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer</title>
      <link>https://6ix.com/company/septerna-inc-common-stock/news/septerna-expands-leadership-appointment-industry-veteran-gil-labrucherie-chief</link>
      <guid isPermaLink="true">https://6ix.com/company/septerna-inc-common-stock/news/septerna-expands-leadership-appointment-industry-veteran-gil-labrucherie-chief</guid>
      <pubDate>Mon, 06 Jan 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G</description>
    </item>
  </channel>
</rss>